Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib for post-COVID-19 pulmonary fibrosis
ChiCTR2000031453Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nintedanib in pulmonary fibrosis (PF) and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tongji Hospital. Primary endpoint: Forced vital capacity. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
nintedanib
03
Conditions
pulmonary fibrosis (PF)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000031453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031453.